Table 2.
Multivariate Cox regression analysis for prognosis risk factors of HCC patients.
| Gene | Parameter | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR | 95%CI Low | 95%CI High | P-value | ||
| SCO2 | Age | 1.01 | 0.995 | 1.025 | 0.188 |
| Gender | 0.962 | 0.647 | 1.431 | 0.849 | |
| Clinical stage | 1.146 | 0.495 | 2.653 | 0.75 | |
| Histologic grade | 1.156 | 0.88 | 1.52 | 0.298 | |
| Tumor stage | 1.483 | 0.666 | 3.303 | 0.335 | |
| SCO2 | 1.295 | 0.982 | 1.708 | 0.067 | |
| ATP7A | Age | 1.013 | 0.998 | 1.029 | 0.094 |
| Gender | 0.977 | 0.655 | 1.456 | 0.908 | |
| Clinical stage | 1.092 | 0.482 | 2.473 | 0.833 | |
| Histologic grade | 1.191 | 0.907 | 1.563 | 0.208 | |
| Tumor stage | 1.517 | 0.699 | 3.292 | 0.292 | |
| ATP7A | 1.508 | 0.925 | 2.458 | 0.099 | |
| FDX1 | Age | 1.011 | 0.996 | 1.026 | 0.16 |
| Gender | 0.961 | 0.646 | 1.43 | 0.846 | |
| Clinical stage | 1.133 | 0.493 | 2.606 | 0.768 | |
| Histologic grade | 1.188 | 0.9 | 1.568 | 0.224 | |
| Tumor stage | 1.487 | 0.673 | 3.284 | 0.327 | |
| FDX1 | 0.914 | 0.68 | 1.228 | 0.549 | |
| LIPT1 | Age | 1.011 | 0.996 | 1.027 | 0.142 |
| Gender | 1.031 | 0.687 | 1.545 | 0.884 | |
| Clinical stage | 1.052 | 0.463 | 2.391 | 0.903 | |
| Histologic grade | 1.178 | 0.898 | 1.545 | 0.237 | |
| Tumor stage | 1.59 | 0.729 | 3.469 | 0.244 | |
| LIPT1 | 1.813 | 1.062 | 3.095 | 0.029* | |
| DLAT | Age | 1.011 | 0.996 | 1.027 | 0.139 |
| Gender | 0.952 | 0.639 | 1.42 | 0.81 | |
| Clinical stage | 1.032 | 0.467 | 2.282 | 0.938 | |
| Histologic grade | 1.165 | 0.891 | 1.525 | 0.264 | |
| Tumor stage | 1.582 | 0.747 | 3.352 | 0.231 | |
| DLAT | 1.481 | 1.13 | 1.941 | 0.004** | |
| PDHA1 | Age | 1.011 | 0.996 | 1.026 | 0.146 |
| Gender | 1.003 | 0.664 | 1.514 | 0.99 | |
| Clinical stage | 1.124 | 0.489 | 2.584 | 0.783 | |
| Histologic grade | 1.221 | 0.934 | 1.597 | 0.145 | |
| Tumor stage | 1.512 | 0.684 | 3.342 | 0.307 | |
| PDHA1 | 1.147 | 0.816 | 1.611 | 0.43 | |
| MTF1 | Age | 1.012 | 0.996 | 1.027 | 0.135 |
| Gender | 0.977 | 0.655 | 1.456 | 0.907 | |
| Clinical stage | 1.146 | 0.506 | 2.596 | 0.744 | |
| Histologic grade | 1.198 | 0.915 | 1.568 | 0.189 | |
| Tumor stage | 1.475 | 0.678 | 3.211 | 0.327 | |
| MTF1 | 1.519 | 0.942 | 2.451 | 0.087 | |
| SLC25A3 | Age | 1.011 | 0.996 | 1.026 | 0.152 |
| Gender | 0.983 | 0.659 | 1.465 | 0.931 | |
| Clinical stage | 1.088 | 0.471 | 2.515 | 0.843 | |
| Histologic grade | 1.203 | 0.921 | 1.572 | 0.175 | |
| Tumor stage | 1.538 | 0.693 | 3.413 | 0.29 | |
| SLC25A3 | 1.281 | 0.869 | 1.889 | 0.211 | |
| AOC1 | Age | 1.011 | 0.995 | 1.026 | 0.177 |
| Gender | 0.958 | 0.643 | 1.427 | 0.831 | |
| Clinical stage | 1.141 | 0.485 | 2.686 | 0.762 | |
| Histologic grade | 1.29 | 0.981 | 1.697 | 0.068 | |
| Tumor stage | 1.467 | 0.648 | 3.321 | 0.358 | |
| AOC1 | 1.31 | 1.038 | 1.653 | 0.023* | |
| TMEM199 | Age | 1.009 | 0.994 | 1.025 | 0.237 |
| Gender | 0.897 | 0.596 | 1.348 | 0.6 | |
| Clinical stage | 1.083 | 0.469 | 2.499 | 0.852 | |
| Histologic grade | 1.169 | 0.891 | 1.534 | 0.258 | |
| Tumor stage | 1.518 | 0.687 | 3.358 | 0.302 | |
| TMEM199 | 1.368 | 0.906 | 2.065 | 0.136 | |
| ATP6AP1 | Age | 1.011 | 0.996 | 1.027 | 0.137 |
| Gender | 0.93 | 0.623 | 1.39 | 0.724 | |
| Clinical stage | 1.093 | 0.477 | 2.508 | 0.833 | |
| Histologic grade | 1.203 | 0.92 | 1.574 | 0.177 | |
| Tumor stage | 1.524 | 0.692 | 3.356 | 0.295 | |
| ATP6AP1 | 1.249 | 0.888 | 1.756 | 0.201 | |
| MT-CO1 | Age | 1.01 | 0.995 | 1.025 | 0.205 |
| Gender | 0.884 | 0.592 | 1.321 | 0.548 | |
| Clinical stage | 1.063 | 0.485 | 2.332 | 0.878 | |
| Histologic grade | 1.147 | 0.875 | 1.504 | 0.322 | |
| Tumor stage | 1.574 | 0.748 | 3.314 | 0.232 | |
| MT-CO1 | 0.744 | 0.6 | 0.924 | 0.007** | |
| ACO1 | Age | 1.011 | 0.996 | 1.026 | 0.15 |
| Gender | 0.943 | 0.633 | 1.405 | 0.774 | |
| Clinical stage | 1.098 | 0.472 | 2.555 | 0.828 | |
| Histologic grade | 1.178 | 0.896 | 1.549 | 0.24 | |
| Tumor stage | 1.531 | 0.685 | 3.423 | 0.299 | |
| ACO1 | 0.864 | 0.663 | 1.127 | 0.281 | |
| COA6 | Age | 1.012 | 0.997 | 1.027 | 0.106 |
| Gender | 0.933 | 0.628 | 1.386 | 0.73 | |
| Clinical stage | 1.106 | 0.475 | 2.577 | 0.815 | |
| Histologic grade | 1.127 | 0.855 | 1.486 | 0.396 | |
| Tumor stage | 1.535 | 0.686 | 3.439 | 0.297 | |
| COA6 | 1.331 | 1.027 | 1.726 | 0.031* | |
| ACP1 | Age | 1.013 | 0.997 | 1.028 | 0.103 |
| Gender | 1.048 | 0.7 | 1.567 | 0.821 | |
| Clinical stage | 1.035 | 0.461 | 2.324 | 0.933 | |
| Histologic grade | 1.122 | 0.855 | 1.473 | 0.407 | |
| Tumor stage | 1.574 | 0.731 | 3.387 | 0.246 | |
| ACP1 | 1.826 | 1.242 | 2.685 | 0.002** | |
| FDX2 | Age | 1.01 | 0.994 | 1.025 | 0.221 |
| Gender | 0.938 | 0.629 | 1.399 | 0.754 | |
| Clinical stage | 1.111 | 0.476 | 2.594 | 0.808 | |
| Histologic grade | 1.185 | 0.903 | 1.555 | 0.222 | |
| Tumor stage | 1.511 | 0.673 | 3.39 | 0.317 | |
| FDX2 | 1.166 | 0.888 | 1.53 | 0.269 | |
| NUBP2 | Age | 1.012 | 0.996 | 1.027 | 0.133 |
| Gender | 0.961 | 0.646 | 1.431 | 0.846 | |
| Clinical stage | 1.144 | 0.494 | 2.651 | 0.753 | |
| Histologic grade | 1.217 | 0.929 | 1.594 | 0.154 | |
| Tumor stage | 1.49 | 0.669 | 3.315 | 0.329 | |
| NUBP2 | 0.958 | 0.652 | 1.408 | 0.828 | |
| CIAPIN1 | Age | 1.01 | 0.995 | 1.025 | 0.201 |
| Gender | 0.959 | 0.644 | 1.427 | 0.835 | |
| Clinical stage | 1.093 | 0.472 | 2.533 | 0.836 | |
| Histologic grade | 1.19 | 0.908 | 1.558 | 0.208 | |
| Tumor stage | 1.525 | 0.686 | 3.391 | 0.3 | |
| CIAPIN1 | 1.228 | 0.864 | 1.745 | 0.252 | |
| ISCA2 | Age | 1.013 | 0.997 | 1.028 | 0.105 |
| Gender | 1.002 | 0.67 | 1.498 | 0.994 | |
| Clinical stage | 1.093 | 0.482 | 2.481 | 0.831 | |
| Histologic grade | 1.204 | 0.919 | 1.577 | 0.179 | |
| Tumor stage | 1.528 | 0.701 | 3.329 | 0.286 | |
| ISCA2 | 1.334 | 0.87 | 2.046 | 0.186 | |
| NDOR1 | Age | 1.013 | 0.997 | 1.029 | 0.101 |
| Gender | 0.995 | 0.666 | 1.486 | 0.98 | |
| Clinical stage | 1.12 | 0.513 | 2.444 | 0.777 | |
| Histologic grade | 1.132 | 0.862 | 1.486 | 0.373 | |
| Tumor stage | 1.461 | 0.698 | 3.061 | 0.315 | |
| NDOR1 | 1.586 | 1.153 | 2.182 | 0.005** | |
ACO1, aconitase 1; ACP1, acid phosphatase 1; AOC1, amine oxidase copper containing 1; ATP6AP1, ATPase H+ transporting accessory protein 1; ATP7A, copper-transporting p-type adenosine triphosphatase 1; CI, confidence interval; CIAPIN1, cytokine induced apoptosis inhibitor 1; COA6, cytochrome c oxidase assembly factor 6; DLAT, dihydrolipoamide S-acetyltransferase; FDX1, ferredoxin 1; FDX2, ferredoxin 2; HR, hazard ratio; ISCA2, iron-sulfur cluster assembly 2; LIPT1, lipoyltransferase 1; MT-CO1, mitochondrially encoded cytochrome c oxidase I; MTF1, metal regulatory transcription factor 1; NDOR1, NADPH dependent diflavin oxidoreductase 1; NUBP2, nucleotide binding protein 2; PDHA1, pyruvate dehydrogenase E1 subunit alpha 1; SCO2, synthesis of cytochrome c oxidase 2; SLC25A3, solute carrier family 25 member 3; TMEM199, transmembrane protein 199; *P < 0.05; **P < 0.01; ***P < 0.001.